Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 329003-65-8 | Product Number: M2289
Monosodium Risedronate Hemipentahydrate
Purity: >98.0%(T)(HPLC)
Synonyms:
- Monosodium 1-Hydroxy-2-(3-pyridyl)ethylidene-1,1-diphosphonate Hemipentahydrate
- Risedronic Acid Monosodium Salt Hemipentahydrate
Product Documents:
Size | Unit Price | Belgium | Japan* | Quantity |
---|---|---|---|---|
100MG |
€74.00
|
1 | 36 |
|
1G |
€486.00
|
1 | 33 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Product Number | M2289 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__7H__1__0NNaO__7P__2·2^^1/__2H__2O = 350.13 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
CAS RN | 329003-65-8 |
Related CAS RN | 115436-72-1&105462-24-6 |
Reaxys Registry Number | 6361090 |
PubChem Substance ID | 135727372 |
Merck Index (14) | 8232 |
MDL Number | MFCD01706268 |
Specifications
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Neutralization titration) | min. 98.0 % |
Water | 11.9 to 13.9 % |
Properties (reference)
Solubility in water | Soluble |
Solubility (insoluble in) | Ethanol |
GHS
Pictogram | |
Signal Word | Warning |
Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. |
Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
Related Laws:
RTECS# | SZ8567500 |
Transport Information:
HS Number | 2933399990 |
Application
Pharmacology Studies
References
- Bisphosphonates Inhibit the Growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A Potential Route to Chemotherapy
- Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
- Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability
Application
Bone Resorption Inhibitors
Reference
- 1)Anti-bone resorption
- a)J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, M. J. Rogers., J. Pharmacol. Exp. Ther. 2001, 296, 235.
- b)E. Hiroi-Furuya, T. Kameda, K. Hiura, H. Mano, K. Miyazawa, Y. Nakamaru, M. Watanabe-Mano, N. Okuda, J. Shimada, Y. Yamamoto, Y. Hakeda, M. Kumegawa, Calcif. Tissue Int. 1999, 64, 219.
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.